The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Treatment for Primary CNS Lymphoma: The Next Step
Abstract
PURPOSE: The use of preradiotherapy (RT) methotrexate (MTX) has improved disease control and survival in patients with primary CNS lymphoma (PCNSL). The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment. PATIENTS AND METHODS: Fifty-two patients were treated with five cycles of high-dose MTX 3.5 g/m 2, procarbazine 100 mg/m 2/d, and vincristine 1.4 mg/m 2. Thirty patients received whole-brain RT (45 Gy). Twenty-two older patients deferred RT to diminish the risk of delayed neurotoxicity; these patients are compared with 12 older patients who completed the entire treatment regimen. Most patients (n = 35) received high-dose cytarabine after RT. RESULTS: Objective response rate to the induction chemotherapy regimen was 90%; overall median survival is 60 months. Grade 3 or 4 myelosuppression was seen in 30 patients, primarily in association with cytarabine; grade 3 nephrotoxicity due to MTX was seen in two patients. Older patients had similar median survival with or without the addition of RT: 32 versus 33 months, respectively. However, late neurotoxicity was significantly more common in those older patients who received RT (P = .00004). Patients younger than 60 years who received the complete treatment regimen have not reached median disease-free or overall survival. CONCLUSION: Increasing the dose of MTX and adding procarbazine and vincristine improved disease control and overall survival in patients with newly diagnosed PCNSL. Younger patients in particular fared extremely well with this treatment regimen. In older patients, deferring whole-brain RT did not compromise overall survival but did reduce treatment-related toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Nelson, D. F., Martz, K. L., Bonner, H., Nelson, J. S., Newall, J., Kerman, H. D., Thomson, J. W., & Murray, K. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90538-s · Cited by 635
Long-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Self-citationCombined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Self-citationNeuwelt, E. A., Goldman, D. L., Dahlborg, S. A., Crossen, J., Ramsey, F., Roman-Goldstein, S., Braziel, R., & Dana, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1580 · Cited by 380
Intravitreal Methotrexate as an Adjunctive Treatment of Intraocular Lymphoma
Fishburne, B. C. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160322009 · Cited by 217
Sa, D., Henner, W. D., Crossen, J. R., Cm, T., Petrillo, A., Braziel, R. M., & Neuwelt, E. A. (1996) · PubMed · Cited by 125
Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease
Soo Borson, B., & Raskind, M. A. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.17s · Cited by 105
Cited by
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Self-citationPrimary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.013 · Cited by 738
Self-citation
Metadata
- Authors
- Abrey, L. E., Yahalom, J., & DeAngelis, L. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-09-17
- Volume
- 18
- Issue
- 17
- Pages
- 3144-3150
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1862506306
- Cited by
- 607
- References
- 9
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.